ChromoCure (KKUR) trades at $0.000001 on 03 Jan 2026 Market hours: micro-volume gain, assess liquidity risk
KKUR (ChromoCure, Inc.) traded at USD 0.000001 on 03 Jan 2026 during market hours on the PNK exchange, marking a micro-volume gain that pushed the day high to USD 0.000002. KKUR stock moved on just 17 shares versus an average daily volume of 2,900,052.00 shares, so price swings reflect extremely thin liquidity rather than broad investor demand. We review what caused the spike, the balance of upside versus liquidity risk, and how the move fits sector trends in Healthcare
Intraday price action and volume
KKUR (ChromoCure, Inc.) reached a day high of USD 0.000002 and closed at USD 0.000001 on 03 Jan 2026 during market hours, with a recorded volume of 17.00 shares versus an average volume of 2,900,052.00 shares, indicating the move was driven by very low liquidity rather than sustained buying pressure.
What drove today’s gain
The recorded change is mechanically large because the previous close in the dataset is effectively zero, producing an anomalous percentage move; there is no public earnings or news release tied to ChromoCure, Inc. that explains the spike, suggesting isolated trades or micro-cap speculative activity in the Medical – Specialties sub-sector.
Liquidity, volatility and trading risks
KKUR’s market capitalization stands at USD 8,200.00 with 8,200,000,000.00 shares outstanding, creating significant bid-ask and execution risk for size; thin intraday liquidity raises the probability of price gaps, and technical indicators in the data show flat or unavailable values, underscoring unreliable signals for technical traders.
Financial profile and valuation
ChromoCure, Inc. operates in Healthcare and lists no EPS or PE ratio in available data, and 50- and 200-day average prices are effectively USD 0.000001, reflecting stagnation; revenue, margins and up-to-date filings are not present in the feed, which limits fundamental valuation beyond market cap and shares outstanding.
Meyka AI grade and technical view
Meyka AI rates KKUR with a score out of 100: Score 62.75, Grade B, Suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The limited data set, near-zero pricing and sparse volume reduce conviction; technical indicators are effectively neutral or unavailable, signaling that the stock is not tradeable for most investors.
Sector context and analyst takeaways
Within the Healthcare sector and Medical – Specialties industry, KKUR is an outlier due to its micro-cap scale and minimal public disclosure; sector performance is not driving this move, so most analyst attention remains on better-capitalized peers while KKUR’s short-term moves are best categorized as speculative.
Final Thoughts
Key takeaways: KKUR stock (ChromoCure, Inc.) traded at USD 0.000001 on 03 Jan 2026 during market hours on the PNK exchange, with a day high of USD 0.000002 and volume of 17.00 shares. Meyka AI’s forecast model projects a base-case short-term price of USD 0.000002, which implies an upside of 100.00% versus the current price of USD 0.000001, while a conservative downside scenario sits near USD 0.0000005 (-50.00%). These model figures are purely projections and not guarantees. Given a market cap of USD 8,200.00, absent EPS or reliable financial disclosures, and an average volume of 2,900,052.00 shares compared to today’s tiny print, KKUR presents extreme liquidity and execution risk. Investors seeking exposure to Healthcare should weigh position size carefully and treat KKUR as speculative; our Meyka AI grade of B and the HOLD suggestion reflect limited data, sector comparison, and elevated trading risk. For active traders, set tight risk controls; for long-term investors, seek clearer financial evidence and a regular news cadence before adding KKUR to a portfolio. Forecasts are model-based projections and not guarantees.
FAQs
The intraday spike to USD 0.000002 occurred on just 17.00 shares; no public earnings or material news were recorded in the feed, so the move is likely due to isolated trades and thin liquidity rather than company fundamentals.
Meyka AI rates KKUR with a score out of 100 at 62.75 (Grade B) and issues a HOLD suggestion; the grade factors in benchmark, sector, financial growth, key metrics and analyst consensus.
Primary risks are extreme illiquidity, limited public financial data, near-zero pricing that inflates percentage moves, and lack of analyst coverage; these increase volatility and execution risk for traders and investors.
Yes, Meyka AI’s forecast model projects a base-case short-term price of USD 0.000002, implying 100.00% upside versus the current USD 0.000001, but forecasts are model-based projections and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
